NASDAQ: RNACCartesian Therapeutics Inc Stock
$10.59+0.41 (+4.03%)
Updated Jul 2, 2026
RNAC Price
$10.59
Fair Value Price
$3.75
Market Cap
$311.15M
52 Week Low
$5.60
52 Week High
$15.57
P/E
-1.79x
P/B
-2.1x
P/S
93.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.78M
Earnings
-$151.77M
Gross Margin
100%
Operating Margin
-9,068.56%
Profit Margin
-8,698.7%
Debt to Equity
-2.95
Operating Cash Flow
-$73M
Beta
1.58
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
RNAC Overview
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNAC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RNAC
Ranked#375 of 463
Ranked#375 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important RNAC news, forecast changes, insider trades & much more!
RNAC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNAC ($10.59) is overvalued by 182.22% relative to our estimate of its Fair Value price of $3.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNAC ($10.59) is not significantly undervalued (182.22%) relative to our estimate of its Fair Value price of $3.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNAC due diligence checks available for Premium users.
Valuation
RNAC fair value
Fair Value of RNAC stock based on Discounted Cash Flow (DCF)
Price
$10.59
Fair Value
$3.75
Overvalued by
182.22%
RNAC ($10.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNAC ($10.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RNAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.79x
Industry
17.59x
Market
8.54x
RNAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.1x
Industry
5.6x
RNAC's financial health
Profit margin
Revenue
$78.0k
Net Income
-$39.2M
Profit Margin
-50,233.3%
RNAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RNAC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$288.4M
Liabilities
$436.5M
Debt to equity
-2.95
RNAC's short-term assets ($122.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNAC's long-term liabilities ($420.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNAC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.1M
Investing
-$27.0k
Financing
$15.7M
RNAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNAC vs Biotech Stocks
Cartesian Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.